Clinical Trial

Study of MHB088C for Patients With Advanced Solid Malignant Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated August 3, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase I/II, multicenter, open-label clinical trial with dose escalation/dose expansion/efficacy expansion phases, designed to evaluate the safety/tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of MHB088C in participants with advanced solid tumors
Trial Details
NCT Number NCT07102004
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Advanced/Metastatic Solid Tumors
Enrollment 515 participants
Start Date 2023-06-20
Primary Completion 2026-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2025-08-03